Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status: Open to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT04711824

Study Contact: studies@hoosiercancer.org; (317) 921-2050.

Abstracts/Posters/Presentations: 

• C Shen, Y Abdou, L Chen, X Tan, G Gupta, F Lynce, M Lobbous, E Stringer-Reasor, C Anders. Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA): Hoosier Cancer Research Network BRE18-360. Poster Presentation, 2023 San Antonio Breast Cancer Symposium. 
• C Shen, Y Abdou, L Chen, X Tan, G Gupta, F Lynce, M Lobbous, E Stringer-Reasor, C Anders. TIPS-21 Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA): Hoosier Cancer Research Network BRE18-360. Trials in Progress, 2023 SNO/ASCO CNS Cancer Conference. See abstract.